E6201 is a flagship candidate of Spirita, which is a potent MEK1 inhibitor with excellent brain penetration (266%). E6201 demonstrated activity in metastatic melanoma, including a patient who maintains an exceptional ongoing durable response lasting for almost 9 years (“E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases” Babiker, H.M., Byron, S.A., Hendricks, W.P.D. et al. Invest New Drugs (2018). A new clinical trial of the E6201 in patients with central nervous system metastases from BRAF+ or MEK-mutated metastatic melanoma in combination with dabrafenib (BRAF inhibitor) is in progress. Spirita also initiated the Global Clinical Development of E6201 in collaboration with JS InnoPharm (Shanghai) Under Strategic Partnership Alliance and Sub-license Agreement.